Immunic (IMUX)
(Delayed Data from NSDQ)
$1.21 USD
-0.06 (-4.72%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $1.21 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
Immunic, Inc. [IMUX]
Reports for Purchase
Showing records 121 - 140 ( 213 total )
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY20; Cash Runway Covers Several Key Milestones in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 Update-Catalyst Rich 2021 with Valuation Offering a Nice Entry Point
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
IMU-838: Encouraging COVID-19 & PSC Results; Selloff Overdone
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
COVID & PSC Programs Upside Makes Undervalued IMUX Even More Attractive
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
In Our View, IMU-838 Remains A Solid Call Option as a COVID Therapeutic
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 IMU-838 Data in PSC to Now Be Reported in 1Q21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
New Publication Further Sets Positive Expectations for COVID Data in 1Q21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
CALVID-1 Trial Progress; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Q3: IMU-838 Headlines Catalyst-Rich in 2021; Pipeline Coming into Sharper Focus
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 Update - Multiple Catalysts Ahead - COVID Data a Solid Call Option
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunic, Inc.
Industry: Medical - Biomedical and Genetics
Reiterating Buy as we Approach Clinical Data Readout from COVID-19 Study
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z